Image from Google Jackets

Systemic Treatment of Prostate Cancer. [E-Book]

By:

Horwich, Alan

Series: Oxford oncology libraryPublication details: Oxford : OUP Oxford, 2010.Description: 1 online resource (102 pages)Content type:

text

Media type:

computer

Carrier type:

online resource

ISBN:

9780191575815
019157581X
1283348330
9781283348331
0199561427
9780199561421

Subject(s):

Online resources:

Kingston Hospital NHS Foundation Trust OpenAthens account holders click here for access

Contents:

Biological principles of hormone therapy -- PSA as a marker of progression and response in advanced prostate cancer -- Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer -- Systemic treatment of recurrence after local therapies -- First-line hormone therapy for metastatic prostate cancer -- Second- and third-line hormone therapies -- Chemotherapy for metastatic prostate cancer -- Role of bisphosphonates in the systemic treatment of prostate cancer -- Systemic isotope therapy of bone metastasis -- Biological targets and new drug development for prostate cancer.

Summary: Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r.

Holdings
Item type	Home library	Class number	URL	Status	Date due	Barcode
Electronic book	Stenhouse Library		Link to resource	Available

Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r.